Full Press Release Details
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2026 financial results and highlighted recent corporate updates. “During the third quarter, we continued to execute across all aspects of our NGN-401 program as we advance toward potential commercialization,” said Rachel McMinn, Ph.D., Founder and Chief Executive Officer